ReviewMedical oncology (Northwood, London, England)2025
Engineered nanoparticles for endocrine tumor targeting, current progress and future outlook.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocrine tumors are hormone-secreting tumors that pose significant challenges for diagnosis and treatment due to their complex biological processes, delayed detection, and poor response to existing therapies. Despite advancements in imaging, surgery, and medicine, tumor heterogeneity, substantial barriers, and systemic toxicity hinder therapeutic success. A novel approach utilizing nanotechnology presents theranostics capabilities for various applications, enhances bioavailability, and ensures precise drug delivery. Engineered nanoparticles (NPs), including lipid-based, polymeric, and inorganic nanocarriers, enable targeted therapy through active targeting (ligand-receptor interactions) or passive accumulation (increased permeability and retention). These nanotechnologies address drug resistance and rapid clearance, delivering treatments directly to tumors while minimizing adverse effects on healthy cells. NPs that mimic biological processes or respond to external stimuli can adapt to the evolving tumor microenvironment. This review focuses on NP-based therapy for endocrine cancer, discussing their mechanisms of action, targeted approaches, and diagnostic and therapeutic applications. The limitations of current therapies and the future prospects of NP-based therapies are explored.
Indexed as
Identifiers
41452564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.